Neurobo Stock Story

NRBO -  USA Stock  

USD 3.29  0.20  6.47%

While some baby boomers are getting worried about healthcare space, it is reasonable to outline Neurobo Pharmaceuticals. We will evaluate why we are still confident in anticipation of a recovery. What is Neurobo Pharmaceuticals valuation so far in 2021? We are going to cover the entity perspective on valuation to give investors a better transparency on taking a position in it.
Published over three months ago
View all stories for Neurobo Pharmaceuticals | View All Stories
Our prognosis on Neurobo Pharmaceuticals (NASDAQ:NRBO) to bounce back in May
This firm currently holds 100 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the firm is not taking enough advantage from borrowing.
The company secures a Beta (Market Risk) of 0.7985, which conveys possible diversification benefits within a given portfolio. Let's try to break down what Neurobo's beta means in this case. As returns on the market increase, Neurobo Pharmaceuticals returns are expected to increase less than the market. However, during the bear market, the loss on holding Neurobo Pharmaceuticals will be expected to be smaller as well. Even though it is essential to pay attention to Neurobo Pharmaceuticals price patterns, it is always good to be careful when utilizing equity historical price patterns. Our philosophy towards estimating any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Neurobo Pharmaceuticals exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Neurobo Pharmaceuticals has an expected return of -0.66%. Please be advised to verify Neurobo Pharmaceuticals downside variance, as well as the relationship between the accumulation distribution and market facilitation index to decide if Neurobo Pharmaceuticals stock performance from the past will be repeated at some point in the near future.
We determine the current worth of Neurobo Pharmaceuticals using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Neurobo Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Neurobo Pharmaceuticals's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Neurobo Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Neurobo Pharmaceuticals. We calculate exposure to Neurobo Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Neurobo Pharmaceuticals's related companies.

Neurobo Pharmaceuticals Investment Alerts

Neurobo investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Neurobo Pharmaceuticals performance across your portfolios.Please check all investment alerts for Neurobo

Neurobo Pharmaceuticals Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Neurobo value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neurobo Pharmaceuticals competition to find correlations between indicators driving the intrinsic value of Neurobo.

How Neurobo utilizes its cash?

To perform a cash flow analysis of Neurobo Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Neurobo Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Neurobo Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Acquisition by Bakshi Akash of 855059 shares of Neurobo Pharmaceuticals subject to Rule 16b-3

Legal trades by Neurobo Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Neurobo insider trading alert for grant of common stock by Bakshi Akash, SVP and COO, on 5th of January 2021. This event was filed by Neurobo Pharmaceuticals I with SEC on 2021-01-05. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Neurobo Pharmaceuticals Further

The big decline in price over the last few months for Neurobo Pharmaceuticalsmay encourage institutional investors to take a closer look at the firm as it is trading at a share price of 3.78 on 134,767 in trading volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in March. However, diversifying your holdings with Neurobo Pharmaceuticals or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days investing horizon is currently 5.07. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Neurobo Pharmaceuticals partners.


Neurobo Pharmaceuticals Earnings Before Interest Taxes and Depreciation Amortization EBITDA is quite stable at the moment. Further, Neurobo Pharmaceuticals Average Assets is decreasing over the last 6 years. The previous year's value of Neurobo Pharmaceuticals Average Assets was 6,162,821. Neurobo Pharmaceuticals Earnings Before Interest Taxes and Depreciation Amortization EBITDA is decreasing over the last 8 years. Further, Neurobo Pharmaceuticals Average Assets is quite stable at the moment.

Neurobo may start a relapse in May

Latest risk adjusted performance indicator falls down to -0.11. Possible price upswing? Neurobo Pharmaceuticals exhibits very low volatility with skewness of -0.28 and kurtosis of 0.3. However, we advise investors to further study Neurobo Pharmaceuticals technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Neurobo Pharmaceuticals' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Neurobo Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Take On Neurobo Pharmaceuticals

Whereas few other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Neurobo Pharmaceuticals may offer a potential longer-term growth to institutional investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither pick up nor drop any shares of Neurobo Pharmaceuticals at this time. The Neurobo Pharmaceuticals risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Neurobo Pharmaceuticals.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Neurobo Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com